Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
GSK3 protein kinase inhibitor CHIR 98014, 5 mg  

GSK3 protein kinase inhibitor CHIR 98014, 5 mg

N*6*-{2-[4-(2,4-Dichloro-phenyl)-5-imidazol-1-yl-pyrimidin-2-ylamino]-ethyl}-3-nitro-pyridine-2,6-diamine

Synonyms: CT 98014
CHIR 98014 is a very potent, cell-permeable reversible inhibitor of GSK-3.

More details

PKI-CHIR980-005

Availability: within 3 days

156,00 €

Background: CHIR 98014 is a very potent, selective, cell-permeable reversible inhibitor of GSK-3α / GSK3β with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.

Chemical formula: C20H17Cl2N9O2
Molecular weight: 486.31 g/mol
Purity: 98 %
Appearance: Light yellow solid
Solubility: Moderately soluble in DMSO
CAS Number: 252935-94-7

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers. 

References

ML Selenica et al. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br. J. Pharmacol. 2007, 152, 959–979.

SE Nikoulina et al. Inhibition of Glycogen Synthase Kinase 3 Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle. Diabetes 2002, 51(7), 2190-2198.

DB Ring et al. Selective glycogen synthase kinase inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003, 52, 588–595.
AS Wagman et al. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des. 2004, 10, 1105–1137.

The following products could also be interesting for you: